An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerations
Authors:
- John D. HorowitzJohn D. Horowitz
- Tamila HeresztynTHTamila Heresztyn
- 1 May 2007
- journal article
- review article
- Published by Elsevier in Journal of Chromatography B
- Vol. 851 (1-2) , 42-50
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serumJournal of Chromatography B, 2005
- Asymmetric Dimethylarginine: A Cardiovascular Risk Factor and a Uremic Toxin Coming of Age?American Journal of Kidney Diseases, 2005
- Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatmentThe American Journal of Cardiology, 2005
- Asymmetric dimethylarginine, homocysteine and renal function – is there a relation?Clinical Chemistry and Laboratory Medicine (CCLM), 2005
- Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevanceClinical Chemistry and Laboratory Medicine (CCLM), 2005
- Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution techniqueJournal of Mass Spectrometry, 2004
- Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortalityClinical Nutrition, 2003
- Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patientsKidney International, 2001
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986